The epidermal growth factor receptor (EGFR) has recently been scrutinised as a potential target in lung adenocarcinoma therapy because of its overexpression in and association with poor prognosis of many solid tumours (Meert et al, 2002; Hirsch et al, 2003). Here, EGFR is linked to lung adenocarcinoma.